Screening for prostate cancer in the UK. Seems to be creeping in by the back door.
作者信息
Donovan J L, Frankel S J, Neal D E, Hamdy F C
出版信息
BMJ. 2001 Oct 6;323(7316):763-4. doi: 10.1136/bmj.323.7316.763.
Abstract
摘要
相似文献
1
Screening for prostate cancer in the UK. Seems to be creeping in by the back door.
BMJ. 2001 Oct 6;323(7316):763-4. doi: 10.1136/bmj.323.7316.763.
2
How valuable is prostate-specific antigen screening?
Minn Med. 1996 Jun;79(6):2.
3
Does screening with prostate/specific antigen improve outcomes?
Minn Med. 1996 Apr;79(4):50-1.
4
Predictive properties of serum prostate-specific antigen testing in a community setting.
Arch Intern Med. 1997;157(15):1765-6. doi: 10.1001/archinte.157.15.1765b.
5
Study questions colorectal and prostate cancer screening priorities.
Rep Med Guidel Outcomes Res. 2003 Apr 4;14(7):1-2, 5.
6
Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
J Clin Oncol. 2011 Feb 1;29(4):345-7. doi: 10.1200/JCO.2010.32.5308. Epub 2010 Dec 28.
7
Studies of prostate-cancer mortality: caution advised.
Lancet Oncol. 2008 May;9(5):407-9. doi: 10.1016/S1470-2045(08)70112-8.
8
Prostate cancer: to screen or not to screen?
Oncology (Williston Park). 1997 Apr;11(4):447-8, 451-2.
9
Prostate cancer: 4. Screening.
CMAJ. 1998 Oct 20;159(8):968-72.
10
Prostate cancer, screening, and prostate-specific antigen: promise or peril?
J Gen Intern Med. 1994 Aug;9(8):468-74. doi: 10.1007/BF02599070.
引用本文的文献
1
Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners.
BMC Fam Pract. 2009 Jan 12;10:3. doi: 10.1186/1471-2296-10-3.
2
Feasibility of familial PSA screening: psychosocial issues and screening adherence.
Br J Cancer. 2006 Feb 27;94(4):507-12. doi: 10.1038/sj.bjc.6602959.
3
Effectiveness and cost-effectiveness of prognostic markers in prostate cancer.
Br J Cancer. 2003 Jan 13;88(1):31-5. doi: 10.1038/sj.bjc.6600630.
4
Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.
CMAJ. 2003 Jan 7;168(1):31-5.
5
"Well, have I got cancer or haven't I?" The psycho-social issues for women diagnosed with ductal carcinoma in situ.
Health Expect. 2002 Dec;5(4):310-8. doi: 10.1046/j.1369-6513.2002.00199.x.
6
Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study.
BMJ. 2002 Oct 5;325(7367):737. doi: 10.1136/bmj.325.7367.737.
7
Demand for prostate specific antigen testing in primary care. Screening through back passage as well as back door?
BMJ. 2002 Mar 2;324(7336):547.
8
The discomfort of patient power.
BMJ. 2002 Mar 2;324(7336):497-8. doi: 10.1136/bmj.324.7336.497.
本文引用的文献
1
Prostate cancer: to screen or not to screen?
Lancet Oncol. 2000 Sep;1(1):17-24. doi: 10.1016/S1470-2045(00)00005-X.
2
How policy informs the evidence.
BMJ. 2001 Jan 27;322(7280):184-5. doi: 10.1136/bmj.322.7280.184.
3
Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer.
JAMA. 2000 Jun 28;283(24):3217-22. doi: 10.1001/jama.283.24.3217.
4
Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998.
BJU Int. 2000 Jun;85(9):1058-62. doi: 10.1046/j.1464-410x.2000.00661.x.
5
Decision aids for patients facing health treatment or screening decisions: systematic review.
BMJ. 1999 Sep 18;319(7212):731-4. doi: 10.1136/bmj.319.7212.731.
6
A randomized controlled trial of shared decision making for prostate cancer screening.
Arch Fam Med. 1999 Jul-Aug;8(4):333-40. doi: 10.1001/archfami.8.4.333.
7
Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom.
BMJ. 1999 Jan 30;318(7179):299-300. doi: 10.1136/bmj.318.7179.299.
8
Preferences of elderly men for prostate-specific antigen screening and the impact of informed consent.
J Gerontol A Biol Sci Med Sci. 1998 May;53(3):M195-200. doi: 10.1093/gerona/53a.3.m195.
9
Diagnosis, management and screening of early localised prostate cancer.
Health Technol Assess. 1997;1(2):i, 1-96.
10
The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team.
J Gen Intern Med. 1996 Jun;11(6):342-9. doi: 10.1007/BF02600045.
Zotero 插件